Co-Diagnostics has the GF Score of 59, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Co-Diagnostics
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Co-Diagnostics (HAM:C970) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Co-Diagnostics GF Score Related Terms
HAM:C970 vs ALRTF, SINT, HSCS: GF Score Comparison
For the Medical Devices subindustry, Co-Diagnostics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's GF Score distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's GF Score falls into.
Co-Diagnostics (HAM:C970) has a GF Score of 59 as of Jul. 02, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Co-Diagnostics and its competitors. This is 23% above median its historical median of 48.00. Over the past decade, Co-Diagnostics' GF Score has ranged from 20.00 to 68.00.
Is Co-Diagnostics' GF Score too high?
Co-Diagnostics' current GF Score of 59 is 23% above median its 10-year median of 48.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 68.00. Overall, Co-Diagnostics has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' GF Score compare to ALRTF and SINT?
Co-Diagnostics' GF Score of 59 can be compared against companies in the Medical Devices & Instruments industry. Historically, Co-Diagnostics' own GF Score has ranged from 20.00 to 68.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current GF Score is 59, which is 23% above median its own 10-year median of 48.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current GF Score of 59. The stock's GF Value™ is €3.83, compared to a current price of €5.55 — trading 44.9% above its estimated fair value. The current GF Score is 59, which is 23% above median its 10-year median of 48.00. Co-Diagnostics' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current GF Score is 59 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 44.9% above its estimated GF Value™ of €3.83.
Key valuation signals for HAM:C970:
GF Score: 59 (23% above median its 10-year median of 48.00)
GF Value™: €3.83 vs. price of €5.55 (44.9% above fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
59GF Score
Get the complete analysis for HAM:C970
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 